2 Most Compelling Stocks to Buy for Long‑Term Investors Right Now

The article argues that Intuitive Surgical and Microsoft are attractive long-term buys despite recent underperformance, citing solid operating trends and durable competitive advantages. Intuitive Surgical posted strong Q1 revenue and procedure growth, expanded its installed base, and saw the da Vinci 5 account for nearly 54% of placed systems, while Microsoft said its AI business reached a $37 billion annual run-rate, up 123% year over year. Microsoft also highlighted a $627 billion cloud backlog and a 153% dividend increase over the past decade, though both stocks face near-term headwinds from tariffs and heavy AI capex.

Analysis

The market is treating both names as “quality at risk,” but the tape is probably underpricing how quickly their current headwinds fade relative to their moats. In both cases, the underlying businesses are still compounding, while the short-term narrative is dominated by input-cost or capex optics; that usually creates an opportunity when the fundamental damage is more about margin timing than demand destruction. The second-order winner is not the obvious stock itself, but the ecosystem around each platform: suppliers tied to procedure volume and enterprise software utilization should keep improving even if headline multiples stay compressed.

For ISRG, the key debate is not whether robotics adoption continues, but whether the installed-base flywheel can offset margin noise from tariffs and newer-system mix. The more important signal is that product iteration and new indications are expanding the addressable procedure pool faster than competitors can build credible switching economics; that tends to re-rate the stock only after utilization data inflects, not when management merely guides through a temporary cost headwind. A subtle catalyst is surgeon familiarity with the latest platform: once the newer systems become the default in placements, service revenue, consumables, and procedure density typically accelerate with a lag of a few quarters.

For MSFT, the bear case is internally inconsistent: if AI were truly commoditizing the product set, the company would not be able to monetize AI at this scale while simultaneously defending enterprise relationships. The real risk is capex elasticity, not demand collapse; if incremental AI spend slows before revenue re-acceleration is visible, the stock can stay range-bound for months despite strong operating trends. The consensus is missing that the backlog and customer lock-in create optionality on multiple monetization layers, so the payoff is less about near-term EPS leverage and more about preserving strategic scarcity in cloud + AI infrastructure.

The contrarian setup is that both names may already be de-rated enough to absorb bad news, while any evidence that growth is simply normalizing rather than breaking would force a fast multiple repair. The highest-probability move is not a straight long into strength, but buying downside protection or expressing relative value versus lower-quality “AI winners” and med-tech peers that lack the same moat durability.

Key Decisions for Investors

• Initiate a staggered long ISRG position over 4-8 weeks; target a 10-15% rebound if procedure growth stays intact and tariff pressure proves transitory. Stop if installed-base growth decelerates for two consecutive quarters.
• Buy MSFT on a 3-6 month horizon with a call-spread structure to reduce capex timing risk; favorable if AI revenue continues compounding faster than cloud spend growth. Risk/reward improves if the stock remains 5-10% below highs while fundamentals hold.
• Pair trade: long MSFT / short a basket of smaller AI infrastructure beneficiaries with weaker cash generation. Thesis: MSFT can monetize AI while competitors remain capex-constrained and valuation-sensitive.
• For ISRG, consider a bullish call spread into the next earnings cycle; the catalyst is not revenue surprise, but evidence that new system adoption is translating into procedure throughput. Best entry is after any post-earnings volatility reset.
• Hold off on adding aggressively to either name if rates back up sharply or if capex commentary accelerates faster than revenue conversion; those are the two conditions most likely to keep both stocks in a prolonged multiple compression regime.